The ImplementatioN of perSonalized medicine In NSCLC in Central Europe: EGFR testing, Histopathology, and clinical feaTures (INSIGHT) observational study assessed both implementation of epidermal growth factor receptor (EGFR) mutation testing and treatment of patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) in a real-world setting in Central Europe. A total of 1785 patients from 14 cancer centers of six Central European countries were enrolled. EGFR mutations were detected in tumors of 13.8% of the patients. More than 70% of patients with advanced EGFR mutation-positive NSCLC received EGFR tyrosine kinase inhibitors as first-line therapy. The INSIGHT study demonstrated the establishment of EGFR mutation testing, a mutation rate consistent with other Caucasian patients populations, and adherence to current guidelines regarding treatment of patients with EGFR mutation-positive tumors in Central Europe.

Boehringer Ingelheim RCV Vienna

Department of Medicine 1 Medical University of Vienna Vienna Austria

Department of Oncology Poznan University of Medical Sciences Poznan Poland

Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic

Medical University of Gdansk Gdansk

Medical University of Graz Graz

Specialized Hospital of St Zoerardus Zobor Nitra Slovakia

The Maria Sklodowska Curie Institute of Oncology Warsaw Poland

University Clinic Golnik Slovenia

References provided by Crossref.org

Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience

NSCLC molecular testing in Central and Eastern European countries